Sun X, Shu Y, Ye G, Wu C, Xu M, Gao R, et al. Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy. Acta Pharm Sin B. 2022;12:838-852 pubmed publisher

Chi Z, Byeon H, Seo E, Nguyen Q, Lee W, Jeong Y, et al. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation. Pharmacol Res. 2019;146:104281 pubmed publisher

Mattioli E, Andrenacci D, Garofalo C, Prencipe S, Scotlandi K, Remondini D, et al. Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS. Aging Cell. 2018;17:e12824 pubmed publisher

Safronova O, Nakahama K, Morita I. Acute hypoxia affects P-TEFb through HDAC3 and HEXIM1-dependent mechanism to promote gene-specific transcriptional repression. Nucleic Acids Res. 2014;42:8954-69 pubmed publisher

Tsukahara T, Haniu H, Matsuda Y. Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells. Int J Med Sci. 2014;11:955-61 pubmed publisher

Zhao H, Jin S, Gewirtz A. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia. J Biol Chem. 2012;287:925-34 pubmed publisher

Thangaraju M, Karunakaran S, Itagaki S, Gopal E, Elangovan S, Prasad P, et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer. 2009;115:4655-66 pubmed publisher